Qlife Holding Ab · OMXSTO:QLIFE
Qlife Holding Ab — Investor Presentation (December 2025)
17 slides from Qlife Holding Ab's investor presentation, December 2025
Slide 1: Bringing lab-quality blood biomarker testing directly to people's homes
Bringing lab- 1 quality blood biomarker testing directly to people’s homes. Disruptive business model: affordable, accessible, and scalable. Convenience, flexibility, and safety at the core of our solution.
Slide 2: Transforming Chronic Disease Management
2 TRANSFORMING CHRONIC DISEASE MANAGEMENT Lab-Quality Home Testing Egoo Health provides accurate blood biomarker testing at home, reducing the need for hospital visits. Accessibility and Affordability The business model makes advanced diagnostics affordable and accessible to a wide population. Conve
Slide 3: Key Partnership Agreement
3 KEY PARTNERSHIP AGREEMENT Strategic Co-Development and Commercial Agreement Qlife and Hipro collaborate to co-develop and commercialize integrated healthcare products for global markets. Market Access and Sales Roles Hipro handles sales in China while Qlife leads sales in EU, UK, and US with royal
Slide 4: Strong partnership with Hipro secures streamlined production and market access
4 KEY PARTNERSHIP Strong partnership with Hipro secures streamlined production and market access • Joint Qlife and Hipro innovation and technology • Applied via dedicated and validated platforms • At a customer price level compatible with home diagnostics
Slide 5: Solutions
5 SOLUTIONS Each of our self-test solutions is aimed at specific applications in major disease areas
Slide 6: Competition
6 COMPETITION Clinical grade test Home-use Lab-use CE/FDA CE/FDA approved approved Lateral flow test
Slide 7: Testing critical biomarkers at home is useful for many types of patients
7 REASONING Testing critical biomarkers at home is useful for many types of patients
Slide 8: Market: decentralized healthcare segments
8 MARKET Our solutions can reach a wide audience by providing essential blood biomarker testing for the fast-growing decentralized healthcare segments Hospital-at-Home Pharmacy Self-test
Slide 9: Business Model
9 BUSINESS MODEL Traditional ways of selling blood in-vitro diagnostics direct-to- consumers suffer from an excessive price point Disruptive advertisement-driven revenue model connects actionable results with consumer products
Slide 10: Traditional, Advanced, Disruptive business models
10 BUSINESS MODEL Traditional Advanced Disruptive Razor blade model Service model Advertisement model Unit sales of devices and tests to Service model with blood data Advertisement-driven model hospitals and institutions delivered to public health systems leveraging Egoo App and data insights Hospit
Slide 11: Road Map
11 ROAD MAP Field Timing Regulatory Partnering Production Egoo royalties Sales China sales US/EU/UK Diabetes 2024 Hipro-A1 HbA1c On-going Established 2026 approved USA Rare disease (PKU) 2025 Egoo-P300 submitted On-going On-going 2026 2026 EU/UK Heart– and kidney failure 2026 Hipro-A1 multiple On-go
Slide 12: Big Addressable Markets
12 BIG ADRESSABLE MARKETS Phenylketonuria Heart Failure Chronic kidney disease Diabetes Rare disease, well defined need Major disease Major disease Major disease Patients worldwide: Patients worldwide: Patients worldwide: Patients worldwide: 150.000 64 million 80 million 500 million Patients adressa
Slide 13: Forecasted Device and Test Volumes
13 PRODUCTION Egoo Health manufactured in China by Hipro Biotechnology Within 3 years reach production of 10M tests and 100k devices -> target 100M/1M in 2030 Cost of goods at a competive price point from start: China production increasing to highly competitive level Test Devices Forecasted Devic
Slide 14: Front-end, data and patient ownership
14 FRONT-END, DATA AND PATIENT OWNERSHIP We want to own the front- end experience, the data layer, and the relationship with the patient Egoo.AI integrate our precise test results with customer-specific personal data to deliver AI generated advice and guidance
Slide 15: Improving the lives of patients with chronic diseases
15 Improving the lives of patients with chronic diseases Empowering people with more accessible ways to manage their health. Convenient, Flexible, Safe.
Slide 16: Team
16 TEAM Thomas Warthoe Kristina Christensen CEO Director QA/RA A seasoned CEO and serial entrepreneur with Expert in IVD and medical devices, with a strong extensive experience in life science and track record in quality assurance, design control, diagnostics. Thomas has developed and exited risk ma
Slide 17: Join Us in Transforming Healthcare
17 Join Us in Transforming Healthcare Scalable Health Solutions Egoo Health delivers scalable solutions that empower individuals to proactively manage their health worldwide. Innovative Diagnostic Platform The platform integrates advanced diagnostics and AI-driven insights to set new standards in pe
Qlife Holding — Investor Presentation (December 2025) on 6ix